

## Supplemental Online Content

Tartof SY, Aliabadi N, Goodwin G, et al. Estimated vaccine effectiveness and respiratory syncytial virus–related lower respiratory tract disease. *JAMA Netw Open*. 2024;7(12):e2450832. doi:10.1001/jamanetworkopen.2024.50832

**eTable 1.** Lower Respiratory Tract Disease Diagnosis Codes (*International Classification of Diseases, Tenth Revision [ICD-10] codes*)

**eTable 2.** LRTD *ICD-10* Code Distribution Between RSV-Positive Cases and RSV-Negative Controls Lower Respiratory Tract Disease Diagnosis Codes

**eTable 3.** Characteristics of Patients Aged 60 Years or Older With LRTD Inpatient or ED Encounters by RSV Testing Approach, Kaiser Permanente Southern California, November 2023 to April 2024

**eTable 4.** Characteristics of Patients Aged 60 Years or Older With LRTD Inpatient or ED Encounters by Vaccination Status, Kaiser Permanente Southern California, November 2023 to April 2024

**eReferences.**

This supplemental material has been provided by the authors to give readers additional information about their work.

**eTable 1. Lower Respiratory Tract Disease Diagnosis Codes (*International Classification of Diseases, Tenth Revision [ICD-10] codes*), Adapted From Rozenbaum et al<sup>1</sup>**

Lower Respiratory Tract Disease (LRTD)		
Value		Description
<b>J09</b>	J09	INFLUNZA D/T ID INFLUNZA VIRUS
	J09.X	FLU D/T IDENT NOVEL FLU A VIRUS
	J09.X1	FLU D/T ID NOVEL FLU A VIRUS W PN
	J09.X2	FLU D/T IDENT NVL FLU A VIRUS W/RES
	J09.X3	FLU D/T IDENT NVL FLU A VIRUS W/GI
	J09.X9	FLU D/T IDENT NVL FLU A VIRUS WOTH
<b>J10</b>	J10	INFLUENZA D/T OTHR IDENT FLU VIRUS
	J10.0	INFLU D/T OTH IDENT FLU W/PNEUMONIA
	J10.00	FLU D/T OTH ID FLU VIRUS W UNSP TYPE PN
	J10.01	INFLU D/T OTH IDENT FLU W/SAM OT PN
	J10.08	FLU D/T OTH ID FLU VIRUS W OTH SPEC PN
	J10.1	INFLUENZA D/T OTHR FLU VIRUS W/RESP
	J10.2	FLU D/T OTH ID FLU VIRUS W GI MANIFEST
	J10.8	INFLUENZA D/T OTHR FLU WOTHR MANI
	J10.81	FLU D/T OTH IDNTF FLU VI W/ENCEPHAP
	J10.82	FLU D/T OTH ID FLU VIRUS W MYOCARDITIS
	J10.83	FLU D/T OTH ID FLU VIRUS W OTITIS MEDIA
	J10.89	FLU D/T OTH ID FLU VIRUS W OTH MANIFEST
<b>J11</b>	J11	INFLUENZA D/T UNIDENT FLU VIRUS
	J11.0	INFLU D/T UNIDENT FLU WTH PNEUMONIA
	J11.00	FLU D/T UNID FLU VIRUS W UNSP TYPE PN
	J11.08	FLU D/T UNID FLU VIRUS W SPEC PN
	J11.1	INFLU D/T UNIDNT FLU VRS WOTH RESP
	J11.2	FLU D/T UNID FLU VIRUS W GI MANIFEST
	J11.8	INFLU D/T UNIDNT FLU VRS WOTH MANF
	J11.81	FLU D/T UNID FLU VIRUS W ENCEPHALOPATHY
	J11.82	FLU D/T UNID FLU VIRUS W MYOCARDITIS

Lower Respiratory Tract Disease (LRTD)		
Value		Description
	J11.83	FLU D/T UNID FLU VIRUS W OTITIS MEDIA
	J11.89	FLU D/T UNID FLU VIRUS W OTH MANIFEST
<b>J12</b>	J12	VIRAL PNEUMONIA, NEC
	J12.0	ADENOVIRAL PN
	J12.1	RESP SYNCYTIAL VIRUS PN
	J12.2	PARAINFLUENZA VIRUS PN
	J12.3	HUMAN METAPNEUMOVIRUS PN
	J12.8	OTH VIRAL PNEUMONIA
	J12.81	PN D/T SARS-ASSOC CORONAVIRUS
	J12.82	PN D/T CORONAVIRUS DISEASE 2019
	J12.89	OTH VIRAL PN
	J12.9	VIRAL PN UNSP
<b>J13</b>	J13	PN D/T STREPTOCOCCUS PNE
<b>J14</b>	J14	PN D/T HEMOPHILUS INFLUENZAE
<b>J15</b>	J15	BACTERIAL PNEUMONIA NEC
	J15.0	PN D/T KLEBSIELLA PNE
	J15.1	PN D/T PSEUDOMONAS
	J15.2	PNEUMONIA DUE TO STAPHYLOCOCCUS
	J15.20	PN D/T STAPH UNSP
	J15.21	PNEUMONIA D/T STAPH AUREUS
	J15.211	PN D/T METHCIL SUSCEPT STAPH AURS
	J15.212	PN D/T METHCIL RESISTANT STAPH AURS
	J15.29	PN D/T OTH STAPH
	J15.3	PN D/T STREPTOCOCCUS GRP B
	J15.4	PN D/T OTH STREPTOCOCCI
	J15.5	PN D/T ESCHERICHIA COLI
	J15.6	PN D/T OTH GRAM-NEGATIVE BACTERIA
	J15.7	PN D/T MYCOPLASMA PNE
	J15.8	PN D/T OTH SPEC BACTERIA

Lower Respiratory Tract Disease (LRTD)		
Value		Description
	J15.9	UNSP BACTERIAL PN
<b>J16</b>	J16	PNEUMONIA D/T OTH INFCT ORGANS NEC
	J16.0	CHLAMYIAL PN
	J16.8	PN D/T OTH SPEC INFCT ORGISMS
<b>J17</b>	J17	PN IN DZ CLS ELSWHR
<b>J18</b>	J18	PNEUMONIA, UNSP ORGANISM
	J18.0	BRONCHOPN UNSP ORGISM
	J18.1	LOBAR PN UNSP ORGISM
	J18.8	OTH PN UNSP ORGISM
	J18.9	PN UNSP ORGISM
<b>J20</b>	J20	ACUTE BRONCHITIS
	J20.0	AC BRONCHIT D/T MYCOPLASMA PNE
	J20.1	AC BRONCHIT D/T HEMOPHILUS INFLUENZAE
	J20.2	AC BRONCHIT D/T STREPTOCOCCUS
	J20.3	AC BRONCHIT D/T COXSACKIEVIRUS
	J20.4	AC BRONCHIT D/T PARAINFLUENZA VIRUS
	J20.5	AC BRONCHIT D/T RESP SYNCYTIAL VIRUS
	J20.6	AC BRONCHIT D/T RHINOVIRUS
	J20.7	AC BRONCHIT D/T ECHOVIRUS
	J20.8	AC BRONCHIT D/T OTH SPEC ORGISMS
	J20.9	AC BRONCHIT UNSP
<b>J21</b>	J21	ACUTE BRONCHIOLITIS
	J21.0	AC BRONCHIO D/T RESP SYNCYTIAL VIRUS
	J21.1	AC BRONCHIO D/T HUMAN METAPNEUMOVIRUS
	J21.8	AC BRONCHIO D/T OTH SPEC ORGISMS
	J21.9	AC BRONCHIO UNSP
<b>J22</b>	J22	UNSP AC LO RESP INFCT
<b>J44.0</b>	J44	OTHR CHR OBSTR PULMONARY DZ
	J44.0	CHRON OBSTR PULM DZ W/AC LO RESP

Lower Respiratory Tract Disease (LRTD)		
Value	Description	
	J44.1	CHRON OBSTR PULM DZ W/EXACERBATION
	J44.9	CHR OBSTRUCTIVE PULM DZ UNSP
<b>J45</b>	J45.21	Asthma with (acute) exacerbation
	J45.22	Asthma with status asthmaticus
	J45.31	Mild persistent asthma with (acute) exacerbation
	J45.32	Mild persistent asthma with status asthmaticus
	J45.41	Moderate persistent asthma with (acute) exacerbation
	J45.42	Moderate persistent asthma with status asthmaticus
	J45.51	Severe persistent asthma with (acute) exacerbation
	J45.52	Severe persistent asthma with status asthmaticus
	J45.901	Other and unspecified asthma with (acute) exacerbation
	J45.902	Other and unspecified asthma with status asthmaticus
<b>J85.x</b>	J85	ABSCESS OF LUNG AND MEDIASTINUM
	J85.0	GANGR&NECR LUNG
	J85.1	ABCS LUNG W PN
	J85.2	ABCS LUNG WO PN
	J85.3	ABCS MEDIASTINUM
<b>J86.x</b>	J86	PYOTHRX
	J86.0	PYOTHRX W FISTULA
	J86.9	PYOTHRX WO FISTULA

**eTable 2. LRTD ICD-10 Code Distribution Between RSV-Positive Cases and RSV-Negative Controls**

LRTD ICD-10 Code	Code Description	RSV negative	RSV positive	Total
<b>J18.9</b>	PN UNSP ORGISM	2,897	168	3,065
<b>J44.1</b>	CHRON OBSTR PULM DZ W/EXACERBATION	990	101	1,091
<b>J44.9</b>	CHR OBSTRUCTIVE PULM DZ UNSP	1,003	51	1,054
<b>J44.0</b>	CHRON OBSTR PULM DZ W/AC LO RESP	844	85	929
<b>J45.901</b>	Other and unspecified asthma with (acute) exacerbation	355	56	411
<b>J44.89</b>	CHRONIC OBSTRUCTIVE ASTHMA W STATUS ASTHMATICUS	255	18	273

<b>J12.82</b>	PN D/T CORONAVIRUS DISEASE 2019	226	3	229
<b>J15.9</b>	UNSPECIFIED BACTERIAL PNEUMONIA	205	21	226
<b>J20.9</b>	AC BRONCHIT UNSP	169	26	195
<b>J12.1</b>	RESP SYNCYTIAL VIRUS PN	16	156	172
<b>J10.1</b>	INFLUENZA D/T OTHR FLU VIRUS W/RESP	140	6	146
<b>J18.1</b>	LOBAR PN UNSP ORGISM	118	7	125
<b>J11.1</b>	INFLU D/T UNIDNT FLU VRS WOTH RESP	117	7	124
<b>J45.41</b>	Moderate persistent asthma with (acute) exacerbation	89	11	100
<b>J20.5</b>	AC BRONCHIT D/T RESP SYNCYTIAL VIRUS	4	77	81
<b>J45.21</b>	Asthma with (acute) exacerbation	67	14	81
<b>J15.1</b>	PN D/T PSEUDOMONAS	76	4	80
<b>J12.89</b>	OTH VIRAL PN	78	0	78
<b>J45.31</b>	Mild persistent asthma with (acute) exacerbation	61	14	75
<b>J12.9</b>	VIRAL PN UNSP	61	5	66
<b>J12.3</b>	HUMAN METAPNEUMOVIRUS PN	56	0	56
<b>J20.8</b>	AC BRONCHIT D/T OTH SPEC ORGISMS	54	1	55
<b>J10.00</b>	FLU D/T OTH ID FLU VIRUS W UNSP TYPE PN	53	1	54
<b>J13</b>	PN D/T STREPTOCOCCUS PNE	27	10	37
<b>J86.9</b>	PYOTHRX WO FISTULA	36	1	37
<b>J15.69</b>	PNEUMONIA DUE TO OTHER GRAM-NEGATIVE BACTERIA	34	0	34
<b>J45.51</b>	Severe persistent asthma with (acute) exacerbation	27	7	34
<b>J15.4</b>	PN D/T OTH STREPTOCOCCI	28	5	33
<b>J20.6</b>	AC BRONCHIT D/T RHINOVIRUS	29	2	31
<b>J15.0</b>	PN D/T KLEBSIELLA PNE	29	0	29
<b>J18.8</b>	OTH PN UNSP ORGISM	28	1	29
<b>J18.0</b>	BRONCHOPN UNSP ORGISM	23	5	28
<b>J10.08</b>	FLU D/T OTH ID FLU VIRUS W OTH SPEC PN	26	1	27
<b>J16.8</b>	PN D/T OTH SPEC INFCT ORGISMS	26	1	27
<b>J11.00</b>	FLU D/T UNID FLU VIRUS W UNSP TYPE PN	25	1	26
<b>J15.212</b>	PN D/T METHCIL RESISTANT STAPH AURS	23	1	24
<b>J15.211</b>	PN D/T METHCIL SUSCEPT STAPH AURS	22	1	23
<b>J10.01</b>	INFLU D/T OTH IDENT FLU W/SAM OT PN	18	0	18
<b>J85.1</b>	ABCS LUNG W PN	16	1	17
<b>J21.0</b>	AC BRONCHIO D/T RESP SYNCYTIAL VIRUS	3	11	14
<b>J21.9</b>	AC BRONCHIO UNSP	13	1	14
<b>J85.0</b>	GANGR&NECR LUNG	13	0	13
<b>J20.4</b>	AC BRONCHIT D/T PARAINFLUENZA VIRUS	12	0	12
<b>J12.2</b>	PARAINFLUENZA VIRUS PN	10	0	10
<b>J14</b>	PN D/T HEMOPHILUS INFLUENZAE	10	0	10

<b>J15.7</b>	PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE	9	0	9
<b>J22</b>	UNSP AC LO RESP INFCT	5	4	9
<b>J11.08</b>	FLU D/T UNID FLU VIRUS W SPEC PN	8	0	8
<b>J15.5</b>	PN D/T ESCHERICHIA COLI	8	0	8
<b>J09.X1</b>	FLU D/T ID NOVEL FLU A VIRUS W PN	7	0	7
<b>J86.0</b>	PYOTHRX W FISTULA	7	0	7
<b>J85.2</b>	ABCS LUNG WO PN	6	0	6
<b>J09.X2</b>	FLU D/T IDENT NVL FLU A VIRUS W/RES	4	1	5
<b>J15.8</b>	PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA	5	0	5
<b>J12.0</b>	ADENOVIRAL PN	3	1	4
<b>J15.61</b>	PNEUMONIA DUE TO ACINETOBACTER BAUMANNII	3	0	3
<b>J21.8</b>	AC BRONCHIO D/T OTH SPEC ORGISMS	3	0	3
<b>J44.81</b>	BRONCHIOLITIS OBLITERANS AND SYNDROME	3	0	3
<b>J45.902</b>	Other and unspecified asthma with status asthmaticus	2	1	3
<b>J12.81</b>	PN D/T SARS-ASSOC CORONAVIRUS	2	0	2
<b>J15.3</b>	PN D/T STREPTOCOCCUS GRP B	2	0	2
<b>J18.2</b>	HYPOSTATIC PNEUMONIA, UNSPECIFIED ORGANISM	2	0	2
<b>J21.1</b>	AC BRONCHIO D/T HUMAN METAPNEUMOVIRUS	2	0	2
<b>J09.X3</b>	FLU D/T IDENT NVL FLU A VIRUS W/GI	1	0	1
<b>J09.X9</b>	FLU D/T IDENT NVL FLU A VIRUS WOTH	1	0	1
<b>J10.2</b>	FLU D/T OTH ID FLU VIRUS W GI MANIFEST	1	0	1
<b>J15.20</b>	PN D/T STAPH UNSP	1	0	1
<b>J15.29</b>	PN D/T OTH STAPH	1	0	1
<b>J16.0</b>	CHLAMYIAL PN	1	0	1
<b>J45.42</b>	Moderate persistent asthma with status asthmaticus	1	0	1
<b>J45.52</b>	Severe persistent asthma with status asthmaticus	1	0	1
<b>Total</b>		8,501	888	9,389

**eTable 3. Characteristics of Patients Aged 60 Years or Older With LRTD Inpatient or ED Encounters by RSV Testing Approach, Kaiser Permanente Southern California, November 2023 to April 2024**

Characteristic	Total Study Population – Tested for RSV	No swab collected/Not Tested for RSV	p-value*	KPSC Standard of Care RSV Testing	Enhanced Salvaged Specimen RSV Testing	p-value**
	<b>N=7,047</b>	<b>N=4,927</b>		<b>N=725</b>	<b>N=6,322</b>	
<b>Age at index date</b>			0.2019			0.1000
60-74	3001 (42.6%)	2156 (43.8%)		288 (39.7%)	2713 (42.9%)	
75+	4046 (57.4%)	2771 (56.2%)		437 (60.3%)	3609 (57.1%)	
<b>Sex</b>			<.0001			0.5764
Female	3819 (54.2%)	2378 (48.3%)		400 (55.2%)	3419 (54.1%)	
Male	3228 (45.8%)	2244 (45.5%)		325 (44.8%)	2903 (45.9%)	
Unknown	--	305 (6.2%)		--	--	
<b>Months of encounter</b>			<.0001			<.0001
Nov-Dec	2275 (32.3%)	1827 (37.1%)		135 (18.6%)	2140 (33.9%)	
Jan-Feb	3733 (53.0%)	1244 (25.2%)		441 (60.8%)	3292 (52.1%)	
Mar-Apr	1039 (14.7%)	1856 (37.7%)		149 (20.6%)	890 (14.1%)	
<b>Race/ethnicity</b>			<.0001			<.0001
Non-Hispanic Asian/Pacific Islander	839 (11.9%)	565 (11.5%)		88 (12.1%)	751 (11.9%)	
Non-Hispanic Black	1197 (17.0%)	902 (18.3%)		185 (25.5%)	1012 (16.0%)	
Hispanic	2323 (33.0%)	1471 (29.9%)		238 (32.8%)	2085 (33.0%)	
Non-Hispanic Multiple/Other/Unknown	86 (1.2%)	372 (7.6%)		5 (0.7%)	81 (1.3%)	
Non-Hispanic White	2602 (36.9%)	1617 (32.8%)		209 (28.8%)	2393 (37.9%)	
<b>Modified Charlson Index Score</b>			<.0001			0.0001
0	474 (6.7%)	682 (13.8%)		27 (3.7%)	447 (7.1%)	
1	660 (9.4%)	456 (9.3%)		51 (7.0%)	609 (9.6%)	
2	856 (12.1%)	604 (12.3%)		82 (11.3%)	774 (12.2%)	
3+	5057 (71.8%)	3185 (64.6%)		565 (77.9%)	4492 (71.1%)	
<b>Number of inpatient encounters in the year before index date</b>			<.0001			0.0050
0	4331 (61.5%)	3310 (67.2%)		407 (56.1%)	3924 (62.1%)	
1	1432 (20.3%)	901 (18.3%)		160 (22.1%)	1272 (20.1%)	
2+	1284 (18.2%)	716 (14.5%)		158 (21.8%)	1126 (17.8%)	
<b>Number of ED encounters in the year before index date</b>			<.0001			0.0451
0	2698 (38.3%)	2058 (41.8%)		270 (37.2%)	2428 (38.4%)	
1	1668 (23.7%)	1193 (24.2%)		151 (20.8%)	1517 (24.0%)	



2+	2681 (38.0%)	1676 (34.0%)		304 (41.9%)	2377 (37.6%)	
<b>Number of outpatient encounters in the year before index date</b>			<.0001			0.5857
<10	2250 (31.9%)	2973 (60.3%)		225 (31.0%)	2025 (32.0%)	
10+	4797 (68.1%)	1954 (39.7%)		500 (69.0%)	4297 (68.0%)	
<b>Comorbidities</b>						
Myocardial infarction	1126 (16.0%)	702 (14.2%)	0.0096	123 (17.0%)	1003 (15.9%)	0.4438
Congestive heart failure	2602 (36.9%)	1565 (31.8%)	<.0001	298 (41.1%)	2304 (36.4%)	0.0138
Cerebrovascular disease	1016 (14.4%)	716 (14.5%)	0.8606	124 (17.1%)	892 (14.1%)	0.0297
Peripheral vascular disease	4823 (68.4%)	3097 (62.9%)	<.0001	517 (71.3%)	4306 (68.1%)	0.0792
Moderate or severe liver disease	120 (1.7%)	69 (1.4%)	0.1914	18 (2.5%)	102 (1.6%)	0.0866
Malignancy	1219 (17.3%)	786 (16.0%)	0.0524	146 (20.1%)	1073 (17.0%)	0.0328
Renal disease	2990 (42.4%)	1817 (36.9%)	<.0001	334 (46.1%)	2656 (42.0%)	0.0363
COPD	3518 (49.9%)	2702 (54.8%)	<.0001	445 (61.4%)	3073 (48.6%)	<.0001
Dementia	851 (12.1%)	560 (11.4%)	0.2356	109 (15.0%)	742 (11.7%)	0.0099
AIDS/HIV	23 (0.3%)	19 (0.4%)	0.5894	6 (0.8%)	17 (0.3%)	0.0125
<b>Diabetes</b>			<.0001			0.0433
Diabetes with A1c $\geq$ 7.5	1098 (15.6%)	659 (13.4%)		108 (14.9%)	990 (15.7%)	
Diabetes with A1c<7.5	2398 (34.0%)	1473 (29.9%)		280 (38.6%)	2118 (33.5%)	
Diabetes with unknown A1c	152 (2.2%)	134 (2.7%)		12 (1.7%)	140 (2.2%)	
No diabetes diagnosis	3399 (48.2%)	2661 (54.0%)		325 (44.8%)	3074 (48.6%)	
<b>RSV Result</b>			N/A			0.0005
Negative	6424 (91.2%)	N/A		686 (94.6%)	5738 (90.8%)	
Positive	623 (8.8%)	N/A		39 (5.4%)	584 (9.2%)	
<b>Encounter setting</b>			<.0001			<.0001
Hospitalization	4024 (57.1%)	2575 (52.3%)		482 (66.5%)	3542 (56.0%)	
Emergency Department	3023 (42.9%)	2352 (47.7%)		243 (33.5%)	2780 (44.0%)	
<b>Immunocompromised</b>			<.0001			0.7635
No	6049 (85.8%)	4372 (88.7%)		625 (86.2%)	5424 (85.8%)	
Yes	998 (14.2%)	555 (11.3%)		100 (13.8%)	898 (14.2%)	
<b>Abrysvo vaccination status</b>			0.0077			<.0001
Did not receive ABRYSVO vaccine	6824 (96.8%)	4726 (95.9%)		680 (93.8%)	6144 (97.2%)	
Received ABRYSVO vaccine	223 (3.2%)	201 (4.1%)		45 (6.2%)	178 (2.8%)	

\*p-value calculated using chi-square, compares characteristics of total RSV tested population versus non-tested population (the latter includes those with no specimen collected)

\*\*p-value calculated using chi-square, compares RSV standard of care testing versus RSV salvage testing

**eTable 4. Characteristics of Patients Aged 60 Years or Older With LRTD Inpatient or ED Encounters by Vaccination Status, Kaiser Permanente Southern California, November 2023 to April 2024**

Characteristic	'Strict Analysis' Unvaccinated N=1,396	'Strict Analysis' Vaccinated N=31	'Strict' p-value	'Broad Analysis' Unvaccinated N=6,824	'Broad Analysis' Vaccinated N=223	'Broad Analysis' p-value
<b>Age at index date</b>						
60-74	627 (44.9%)	12 (38.7%)	0.492	2936 (43%)	65 (29.1%)	<0.0001
75+	769 (55.1%)	19 (61.3%)		3888 (57%)	158 (70.9%)	
<b>Sex</b>						
Female	799 (57.2%)	17 (54.8%)	0.7897	3704 (54.3%)	115 (51.6%)	0.4242
Male	597 (42.8%)	14 (45.2%)		3120 (45.7%)	108 (48.4%)	
<b>Months of encounter</b>						
Nov-Dec	504 (36.1%)	1 (3.2%)	0.0006	2254 (33%)	21 (9.4%)	<0.0001
Jan-Feb	700 (50.1%)	22 (71%)		3587 (52.6%)	146 (65.5%)	
Mar-Apr	192 (13.8%)	8 (25.8%)		983 (14.4%)	56 (25.1%)	
<b>Race/ethnicity</b>						
Non-Hispanic Asian/Pacific Islander	188 (13.5%)	5 (16.1%)	0.2413	796 (11.7%)	43 (19.3%)	0.0001
Non-Hispanic Black	182 (13%)	6 (19.4%)		1158 (17%)	39 (17.5%)	
Hispanic	529 (37.9%)	6 (19.4%)		2275 (33.3%)	48 (21.5%)	
Non-Hispanic Multiple/Other/Unknown	23 (1.6%)	0 (0%)		86 (1.3%)	0 (0%)	
Non-Hispanic White	474 (34%)	14 (45.2%)		2509 (36.8%)	93 (41.7%)	
<b>Modified Charlson Index Score</b>						
0	110 (7.9%)	1 (3.2%)	0.5553	465 (6.8%)	9 (4%)	0.0643
1	152 (10.9%)	4 (12.9%)		641 (9.4%)	19 (8.5%)	
2	177 (12.7%)	6 (19.4%)		818 (12%)	38 (17%)	
3+	957 (68.6%)	20 (64.5%)		4900 (71.8%)	157 (70.4%)	
<b>Number of inpatient encounters in the year before index date</b>						
0	976 (69.9%)	22 (71%)	0.7847	4184 (61.3%)	147 (65.9%)	0.3723
1	231 (16.5%)	6 (19.4%)		1391 (20.4%)	41 (18.4%)	
2+	189 (13.5%)	3 (9.7%)		1249 (18.3%)	35 (15.7%)	
<b>Number of ED encounters in the year before index date</b>						
0	588 (42.1%)	13 (41.9%)	0.976	2597 (38.1%)	101 (45.3%)	0.0144
1	335 (24%)	7 (22.6%)		1632 (23.9%)	36 (16.1%)	
2+	473 (33.9%)	11 (35.5%)		2595 (38%)	86 (38.6%)	

<b>Number of outpatient encounters in the year before index date</b>						
<10	449 (32.2%)	4 (12.9%)	0.0227	2008 (29.4%)	25 (11.2%)	<0.0001
10+	947 (67.8%)	27 (87.1%)		4816 (70.6%)	198 (88.8%)	
<b>Comorbidities</b>						
Myocardial infarction	187 (13.4%)	4 (12.9%)	0.9366	1089 (16%)	37 (16.6%)	0.7994
Congestive heart failure	461 (33%)	8 (25.8%)	0.3975	2515 (36.9%)	87 (39%)	0.5111
Cerebrovascular disease	171 (12.2%)	1 (3.2%)	0.1269	996 (14.6%)	20 (9%)	0.0186
Peripheral vascular disease	931 (66.7%)	22 (71%)	0.617	4652 (68.2%)	171 (76.7%)	0.0071
Moderate or severe liver disease	18 (1.3%)	1 (3.2%)	0.3522	116 (1.7%)	4 (1.8%)	0.9151
Malignancy	221 (15.8%)	7 (22.6%)	0.3104	1174 (17.2%)	45 (20.2%)	0.2477
Renal disease	570 (40.8%)	15 (48.4%)	0.3975	2902 (42.5%)	88 (39.5%)	0.3622
COPD	679 (48.6%)	18 (58.1%)	0.2991	3385 (49.6%)	133 (59.6%)	0.0032
Dementia	169 (12.1%)	1 (3.2%)	0.1311	834 (12.2%)	17 (7.6%)	0.0381
AIDS/HIV	2 (0.1%)	0 (0%)	0.833	22 (0.3%)	1 (0.4%)	0.7454
<b>Diabetes</b>						
Diabetes with A1c $\geq$ 7.5	225 (16.1%)	3 (9.7%)	0.7935	1078 (15.8%)	20 (9%)	0.005
Diabetes with A1c<7.5	450 (32.2%)	11 (35.5%)		2331 (34.2%)	67 (30%)	
Diabetes with unknown A1c	32 (2.3%)	1 (3.2%)		147 (2.2%)	5 (2.2%)	
No diabetes diagnosis	689 (49.4%)	16 (51.6%)		3268 (47.9%)	131 (58.7%)	
<b>RSV Result</b>						
Negative	775 (55.5%)	29 (93.5%)	<0.0001	6203 (90.9%)	221 (99.1%)	<0.0001
Positive	621 (44.5%)	2 (6.5%)		621 (9.1%)	2 (0.9%)	
<b>Encounter setting</b>						
Hospitalization	679 (48.6%)	13 (41.9%)	0.4601	3910 (57.3%)	114 (51.1%)	0.0667
Emergency Department	717 (51.4%)	18 (58.1%)		2914 (42.7%)	109 (48.9%)	
<b>Immunocompromised</b>						
No	1201 (86%)	26 (83.9%)	0.7318	5861 (85.9%)	188 (84.3%)	0.5046
Yes	195 (14%)	5 (16.1%)		963 (14.1%)	35 (15.7%)	

## eReferences

1. Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States. *Infect Dis Ther.* Feb 2023;12(2):677-685. doi:10.1007/s40121-023-00758-5